Radiation before knife: small study tests new pancreatic cancer approach
NCT ID NCT04128332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving a short, strong dose of radiation right before surgery is possible for people with pancreatic cancer. Ten patients took part to see if the approach was safe and could help surgeons remove the tumor completely. The main goal was to check for complications within 30 days after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
Oct 2020
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
16 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria Stage 1: * Have given written informed consent to participate in stage 1 * Be aged 16 years or over at the time of signing the informed consent form * Presence of a hypodense pancreatic mass on contrast enhanced CT scan highly suspicious of operable primary pancreatic cancer as assessed by a pancreatic multi-disciplinary team (MDT) * Have not had pre-operative systemic therapy or radiotherapy Inclusion Criteria Stage 2: * Have participated in stage 1 of the study * Have confirmed histological or cytological diagnosis of primary pancreatic adenocarcinoma OR radiological evidence of pancreatic head mass with supportive cytological or histological findings. * Be scheduled to undergo pancreatico-duodenectomy (Whipple's) resection. * Written informed consent to participate in stage 2 * Aged 16 years or over at the time of signing informed consent * Have not had pre-operative systemic therapy or radiotherapy * ECOG Performance status 0-1 * Adequate renal function: GFR ≥ 60 Exclusion Criteria: * Any condition or abnormalities that in the judgement of the investigator/surgeon/clinical oncologist would place the patient at undue risk * Women who are known to be pregnant * Previous abdominal radiotherapy * Women of child-bearing potential who are unwilling to use 2 highly effective forms of contraception during the study treatment period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer of pancreas are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrookes Hospital
Cambridge, Cb2 0QQ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can digital questionnaires improve life during pancreatic cancer therapy?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- New chemo cocktail targets pancreatic cancer at every stage
- Blood thinner flush could boost tumor biopsy success
- Blood test aims to catch Cancer's return earlier
- Blood test guides immunotherapy for hidden cancer cells